Results 91 to 100 of about 33,171 (260)

Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia [PDF]

open access: yes, 2008
3openA.
Ania   +21 more
core   +1 more source

Superior Vena Cava Syndrome in a Patient with Polycytemia Vera: Diagnosis and Treatment

open access: yesCardiology Research and Practice, 2010
Polycythemia vera is a myeloproliferative disorder characterized by thrombotic complications both in the arterial and venous systems. We report the case of a 55-year-old patient affected by polycythemia vera, presenting with acute superior vena cava ...
Salvatore Lentini   +3 more
doaj   +1 more source

Idiopathic noncirrhotic portal hypertension: current perspectives [PDF]

open access: yes, 2016
The term idiopathic noncirrhotic portal hypertension (INCPH) has been recently proposed to replace terms, such as hepatoportal sclerosis, idiopathic portal hypertension, incomplete septal cirrhosis, and nodular regenerative hyperplasia, used to describe ...
D'AMATI, Giulia   +5 more
core   +1 more source

Outcomes of Cerebral Venous Thrombosis in Patients With Myeloproliferative Neoplasms from a U.S. Nationwide Hospitalization Study

open access: yes
eJHaem, Volume 7, Issue 1, February 2026.
Nikhil Vojjala   +6 more
wiley   +1 more source

Koljusisesed verevalumid tõelise polütsüteemiaga haigel kerge trauma järel [PDF]

open access: yes, 2017
Tõelise polütsüteemia diagnoosiga 54aastasel naishaigel kujunesid pärast kerget traumat – omalt jalalt kukkumist – ajusisene ja subduraalne verevalum vasemas ajupoolkeras.
Hein, Marju   +3 more
core   +2 more sources

Policitemia vera en un perro : su diagnóstico y su tratamiento [PDF]

open access: yes, 2001
En este artículo presentamos un caso clínico de policitemia vera (eritrocitosis) canina con un nivel de eritropoyetina en suero normal.
Anguiano, E.   +3 more
core  

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]

open access: yes, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M.   +14 more
core   +1 more source

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)

open access: yesHaematologica, 2018
The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia.
Ronan Le Calloch   +13 more
doaj   +1 more source

Polycythemia rubra vera and Hairy Cell Leukaemia / Reply [PDF]

open access: bronze, 1985
G J Mufti   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy